InflaRx (IFRX) EBT Margin Growth (1y) (2019 - 2026)
InflaRx (IFRX) EBT Margin Growth (1y) (2019 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -153.00 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -571.00 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 546.00 |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 4,709.00 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1,076.00 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1,911.00 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -2,507.00 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 29,565.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -392.00 |
| 10 | InflaRx | 140.30 Mn | -43.96 Mn | 2.74 Bn | 1.55 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.51 Mn |
| Dec 31, 2025 | -883.00 |
| Sep 30, 2025 | -2.61 Mn |
| Jun 30, 2025 | 19.75 Mn |
| Mar 31, 2025 | -258,499.00 |
| Dec 31, 2024 | 11,040.00 |
| Sep 30, 2024 | -1.18 Mn |
| Jun 30, 2024 | -22.95 Mn |
| Mar 31, 2024 | -3.21 Mn |
| Dec 31, 2023 | 413,741.00 |
| Sep 30, 2023 | -54,147.00 |
| Jun 30, 2023 | 49,522.00 |
| Mar 31, 2023 | -152,530.00 |
| Dec 31, 2022 | -61.30 Mn |
| Sep 30, 2022 | -88,323.00 |
| Jun 30, 2022 | 14,873.00 |
| Mar 31, 2022 | 137,913.00 |
| Dec 31, 2021 | 30.65 Mn |
| Sep 30, 2021 | 357,382.00 |
| Jun 30, 2021 | -177,207.00 |